A vaccine that works, but only if people use it
For two decades, a vaccine has existed that can prevent certain cancers caused by human papillomavirus — yet half of American teenagers remain unvaccinated, and men in particular are paying the price in rising rates of head and neck cancers they never knew the virus could cause. The gap between what medicine can offer and what society chooses to accept is not a scientific failure but a human one, shaped by hesitancy, incomplete awareness, and a persistent misperception that HPV is a concern for women alone. Prevention, in this case, was never the hard part — the harder work is closing the distance between knowledge and action.
- Men are receiving cancer diagnoses — throat, mouth, head and neck — caused by a virus they never knew threatened them, arriving in doctors' offices years after a vaccine could have changed everything.
- Only half of American teenagers are fully vaccinated against HPV, a rate that lags far behind other preventive shots not because the vaccine is less safe, but because awareness and acceptance have failed to keep pace with the science.
- Vaccination hesitancy runs deep: parents fear side effects despite decades of safety data, underestimate HPV's danger to sons, and carry an unspoken discomfort with the virus's sexual transmission route that quietly suppresses uptake for boys.
- Doctors are watching two realities unfold simultaneously — cancer rates falling in vaccinated cohorts, and preventable cases still walking through clinic doors — making the urgency of the message impossible to ignore.
- Public health officials and the medical community are pushing harder on awareness, honest communication about hesitancies, and normalizing HPV vaccination for boys with the same cultural ease it has found for girls.
A man in his forties is diagnosed with throat cancer — not from smoking, not from anything he recognized as a risk, but from a virus he'd never associated with himself. He survived, but was left with a haunting realization: a vaccine had existed for years that could have prevented it entirely, and no one had ever told him.
This story is becoming less exceptional. Across the country, men are developing HPV-related head and neck cancers at rising rates, even as the virus has long been understood to cause cervical cancer in women. The HPV vaccine has been FDA-approved since 2006, proven effective not just in trials but in the real world — where vaccination rates rise, cancer rates fall. And yet barely half of American teenagers are receiving it.
The reasons are layered. Parents worry about side effects despite extensive safety records. Many don't realize HPV causes cancers in men at all. A quiet discomfort around sexual transmission has kept uptake lower for boys than for girls. Public health messaging has improved, but the gap remains wide and consequential.
The human cost is measurable. Men who were never vaccinated in their youth are now undergoing surgery, radiation, and chemotherapy for cancers that a simple injection could have stopped. Some don't survive. The vaccine doesn't merely reduce risk — administered before exposure, it essentially eliminates the threat.
Doctors watching this unfold are growing more urgent in their message. The tool exists. The science is settled. What remains is the harder work: shifting awareness about HPV's danger to men, meeting hesitancy with honest information, and extending to boys the same normalized protection that vaccination has long offered girls. The next generation's outcomes will depend on whether that gap finally closes.
A man in his forties or fifties walks into a doctor's office with a sore throat that won't go away. Weeks pass. The diagnosis arrives like a thunderbolt: cancer. Not lung cancer, not from smoking, but something he'd never heard of—a cancer caused by a virus most people associate with women. He survived, but the experience left him shaken by a simple fact: there was a vaccine that could have prevented this entirely, and he never knew it existed.
This man's story is no longer unusual. Across the country, men are developing head and neck cancers caused by human papillomavirus, or HPV, at rising rates. The virus, which can be sexually transmitted, has long been known to cause cervical cancer in women. But it also causes cancers of the throat, mouth, and other tissues in both men and women. What makes this moment different is that we have had a tool to stop it for two decades. The HPV vaccine received FDA approval in 2006. It works. It prevents the virus from taking hold. And yet, barely half of American teenagers are getting vaccinated.
The disconnect is stark and consequential. In Wisconsin and elsewhere, public health officials point to clear evidence: where vaccination rates climb, cancer rates fall. The vaccine has proven itself in the real world, not just in clinical trials. But uncertainty persists. Parents hesitate. Teens don't get the shots. And men who should have been protected in their youth are now facing diagnoses that could have been prevented with a simple injection.
The stakes are personal and measurable. Every year, more men develop HPV-related cancers, many of them unaware that the virus was even a threat to them. They undergo surgery, radiation, chemotherapy—treatments that are brutal and life-altering. Some don't survive. The tragedy is compounded by the fact that prevention was available. The vaccine doesn't just reduce risk; it essentially eliminates the threat if given before exposure to the virus.
Vaccination hesitancy operates on multiple levels. Some parents worry about side effects, despite decades of safety data. Others question whether the vaccine is necessary for their sons, not fully grasping that HPV causes cancers in men too. There's also a lingering discomfort around the sexual transmission route—a squeamishness that translates into lower uptake rates for boys compared to girls. Public health messaging has improved, but it hasn't closed the gap.
The numbers tell the story. Only about fifty percent of teenagers are fully vaccinated against HPV. That means half of each generation is entering adulthood without protection. For comparison, vaccination rates for other preventive shots are substantially higher. The difference isn't that HPV vaccine is less safe or less effective. It's that awareness and acceptance lag behind the science.
Doctors in states like Wisconsin are watching this play out in their clinics. They see the vaccine working—cancer rates declining in vaccinated cohorts. But they also see the preventable cases arriving in their offices: men in their thirties, forties, and beyond, diagnosed with cancers that a vaccine could have stopped. The message from the medical community is increasingly urgent: this is a cancer prevention strategy that works, but only if people use it.
The path forward requires both individual choice and public health effort. Increasing awareness about HPV's role in male cancers could shift perceptions. Addressing specific vaccine hesitancies with clear, honest information matters. And normalizing HPV vaccination for boys the way it has been for girls would close a protection gap that currently leaves millions vulnerable. The vaccine is there. The question is whether the next generation will have access to it—and whether their parents will choose to use it.
Notable Quotes
Something I'd never heard of almost killed me— A man diagnosed with HPV-related cancer
The Hearth Conversation Another angle on the story
Why does it matter that men are getting these cancers now, specifically? Isn't cancer prevention always important?
It matters because this is preventable. We're not talking about a disease we don't understand or can't stop. We have a vaccine that works. The tragedy is that men are suffering from something their generation could have been protected against as teenagers.
But the vaccine has been around for twenty years. Why is this becoming a story now?
Because the rates are rising. As the vaccinated generation ages, we're seeing the contrast—fewer cancers in people who got the shot, more in those who didn't. And awareness is finally catching up to the fact that this isn't just a women's health issue.
What's the actual barrier? Is it safety concerns, or something else?
It's mixed. Some parents worry about side effects, but the real issue is often invisibility. HPV doesn't feel like a threat to boys the way it does to girls. The sexual transmission route makes people uncomfortable. And many men don't know the virus causes throat and mouth cancers at all.
So it's not that the vaccine doesn't work?
No. The vaccine works remarkably well. Where vaccination rates are high, cancer rates drop. The problem is that only half of teenagers are getting it. That's a choice problem, not a science problem.
What happens to the men who don't get vaccinated?
Some never encounter the virus and live their whole lives fine. Others get infected, and some of those develop cancer years later. They end up in surgery, radiation, chemotherapy. Some die. All of it preventable.
What would change the vaccination rate?
Honest conversation about what HPV actually does, especially in men. Better messaging from doctors. And probably just time—as more people see the vaccine working in their own communities, hesitancy tends to fade.